ATE475716T1 - Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen - Google Patents

Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen

Info

Publication number
ATE475716T1
ATE475716T1 AT02760784T AT02760784T ATE475716T1 AT E475716 T1 ATE475716 T1 AT E475716T1 AT 02760784 T AT02760784 T AT 02760784T AT 02760784 T AT02760784 T AT 02760784T AT E475716 T1 ATE475716 T1 AT E475716T1
Authority
AT
Austria
Prior art keywords
compositions
treatment
neurodegenerative diseases
subjects
methods
Prior art date
Application number
AT02760784T
Other languages
English (en)
Inventor
Keiya Ozawa
Shin-Ichi Muramatsu
Kunihiko Ikeguchi
Imaharu Nakamo
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23226283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE475716(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of ATE475716T1 publication Critical patent/ATE475716T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT02760784T 2001-08-29 2002-08-29 Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen ATE475716T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31583801P 2001-08-29 2001-08-29
PCT/JP2002/008761 WO2003018821A2 (en) 2001-08-29 2002-08-29 Compositions and methods for treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
ATE475716T1 true ATE475716T1 (de) 2010-08-15

Family

ID=23226283

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02760784T ATE475716T1 (de) 2001-08-29 2002-08-29 Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen

Country Status (10)

Country Link
US (1) US20030050273A1 (de)
EP (1) EP1421199B1 (de)
JP (1) JP4279141B2 (de)
KR (1) KR20040039316A (de)
CN (1) CN1304581C (de)
AT (1) ATE475716T1 (de)
AU (1) AU2002326163B2 (de)
CA (1) CA2457057C (de)
DE (1) DE60237158D1 (de)
WO (1) WO2003018821A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6815431B2 (en) 1998-04-15 2004-11-09 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
EP1463530A4 (de) * 2001-12-19 2006-09-06 Lijun Wang Adeno-assoziierte virusvermittelte abgabe von gdnf an skelettmuskeln
US6998118B2 (en) * 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
IL162630A0 (en) * 2001-12-21 2005-11-20 Salk Inst For Biological Studi A composition containing a viral vector containinga heterologous gene to be transduced into a neuron
US20060258576A1 (en) * 2003-09-05 2006-11-16 Licentia, Ltd Gdnf-related neuropeptides
BRPI0415563A (pt) 2003-10-20 2007-01-02 Nsgene As método para o tratamento do mal de parkinson, uso de um vetor viral, vetor de expressão viral, composição farmacêutica, célula hospedeira isolada, linhagem de células de empacotamento, mamìfero não humano quimérico, dispositivo de cultura celular implantável, cápsula biocompatìvel, método para tratamento de uma doença do sistema nervoso, célula de mamìfero, e, método para produzir neurturin ou um seu equivalente funcional
WO2005074605A2 (en) * 2004-02-03 2005-08-18 University Of Rochester Recombinant molecular products for expression of heme oxygenase-1, heme oxygenase-2, and/or biliverdin reductase for treatment of neurodegenerative diseases or disorders
JP4779120B2 (ja) 2004-07-02 2011-09-28 国立大学法人大阪大学 内視鏡アタッチメントおよび内視鏡
CA2606490C (en) 2005-05-02 2018-02-06 Genzyme Corporation Gene therapy for spinal cord disorders
JP5829372B2 (ja) * 2005-05-02 2015-12-09 ジェンザイム・コーポレーション 神経代謝性疾患のための遺伝子治療
EP2389191A2 (de) 2009-01-23 2011-11-30 NsGene A/S Expression von neuropeptiden in säugetierzellen
JP2012516357A (ja) * 2009-01-29 2012-07-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 神経学的障害を治療するための皮質全体に亘る高レベルの治療薬の分布方法
HRP20250897T1 (hr) * 2009-05-02 2025-09-26 Genzyme Corporation Genska terapija za neurodegenerativne poremećaje
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
WO2012057363A1 (ja) 2010-10-27 2012-05-03 学校法人自治医科大学 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
CN102618507B (zh) * 2012-03-23 2015-04-22 首都医科大学 增加腺相关病毒靶向转导效率的重组腺相关病毒及其应用
US8999927B2 (en) 2012-04-02 2015-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glial cell line-derived neurotrophic factor (GDNF) compositions and use thereof
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
CN107073051B (zh) 2014-10-21 2021-08-24 马萨诸塞大学 重组aav变体及其用途
AU2017341849B2 (en) 2016-10-13 2024-03-21 University Of Massachusetts AAV capsid designs
JP7215716B2 (ja) 2017-01-13 2023-01-31 学校法人自治医科大学 肝臓ゲノム上の凝固関連因子遺伝子を破壊するためのａａｖベクター
EP3744846A4 (de) 2018-01-26 2021-11-17 Tokushima University Adeno-assoziiertes virus-virion zur behandlung von morbus tay-sachs und morbus sandhoff
CN110499330A (zh) * 2018-05-16 2019-11-26 上海市同济医院 重组腺相关病毒载体及其应用
EP3831949A4 (de) 2018-07-30 2022-05-04 Gene Therapy Research Institution Co., Ltd. Verfahren zur erhöhung der genexpression durch einen aav-vektor
WO2020093035A1 (en) 2018-11-02 2020-05-07 The Johns Hopkins University Adenoviral chimeric tdp-43 proteins
US20220265853A1 (en) 2019-07-12 2022-08-25 Gene Therapy Research Institution Co., Ltd. Adeno-associated virus virion for gene transfer to human liver
WO2022224372A1 (ja) 2021-04-21 2022-10-27 学校法人自治医科大学 オルニチントランスカルバミラーゼ欠損症の治療用アデノ随伴ウイルスビリオン
TW202325850A (zh) * 2021-11-29 2023-07-01 大陸商上海瑞宏迪醫藥有限公司 Aadc、gdnf多核苷酸及其用於治療帕金森病
EP4511482A4 (de) * 2022-04-19 2026-03-18 Shanghai Vitalgen Biopharma Co Ltd Rekombinante aav-vektoren zur behandlung neurodegenerativer erkrankungen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
AU679167B2 (en) * 1991-09-20 1997-06-26 Amgen, Inc. Glial derived neurotrophic factor
WO1995005864A1 (en) * 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
ATE386131T1 (de) * 1994-04-13 2008-03-15 Univ Rockefeller Aav-vermittelte überbringung von dna in zellen des nervensystems
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US6057122A (en) * 1996-05-03 2000-05-02 Abbott Laboratories Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis
WO1999061066A2 (en) * 1998-05-27 1999-12-02 Avigen, Inc. Convection-enhanced delivery of aav vectors
CN1228995A (zh) * 1999-01-26 1999-09-22 卢杲 一种治疗老年性痴呆症、帕金森症、心脑血管病的药物
US6800281B2 (en) * 2000-11-09 2004-10-05 Oxford Biomedica (Uk) Limited Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases

Also Published As

Publication number Publication date
CN1575340A (zh) 2005-02-02
CA2457057C (en) 2011-05-10
JP4279141B2 (ja) 2009-06-17
DE60237158D1 (de) 2010-09-09
CN1304581C (zh) 2007-03-14
WO2003018821A3 (en) 2003-10-30
EP1421199B1 (de) 2010-07-28
CA2457057A1 (en) 2003-03-06
JP2005501127A (ja) 2005-01-13
WO2003018821A2 (en) 2003-03-06
KR20040039316A (ko) 2004-05-10
EP1421199A2 (de) 2004-05-26
AU2002326163B2 (en) 2007-10-25
US20030050273A1 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
DE60237158D1 (de) Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
NO974767D0 (no) Anvendelse av glianeurotrof faktor (GDNF) til behandling av hörselssykdommer
ATE451929T1 (de) Von casein abgeleitete peptide und deren anwendung für die therapie
WO2005081628A3 (en) Casein derived peptides and therapeutic uses thereof
EA200901299A1 (ru) Композиции олигогулуроната и олигогалактуроната
ATE489956T1 (de) Formulierungen enthaltend salicylate und deren verwendung zur behandlung von entzündlicher darmerkrankung
BR112014016557A2 (pt) métodos de tratamento de sintomas comportamentais de distúrbios neurológicos e mentais
NZ515964A (en) A method for the prophylaxis and/or treatment of medical disorders
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
EP1251126A3 (de) Fluor-substituierte benzensulfonyl-derivate zur behandlung von entzündungen
Tak et al. Oral submucous fibrosis: A review article on etiopathogenesis
ATE407690T1 (de) Topische pharmazeutische zusammensetzungen enthaltend aktive natürliche bestandteile zur verhütung und behandlung von mucosalen entzündungprozessen
EP4225382A4 (de) Therapeutische adeno-assoziierte virusverabreichung von fkutin-verwandtem protein (fkrp) zur behandlung von dystroglycanopathie. erkrankungen mit gliedmassengürtel 21
DE69819488D1 (de) Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
WO2007132292A3 (en) Therapy for alzheimer's disease
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
WO2003087325A3 (en) Methods and compositions for preventing and treating microbial infections
ATE277625T1 (de) Pharmazeutische zusammensetzung aus spinnengiften sowie deren herstellung und verwendung zur behandlung von tumorerkrankungen
DE60129606D1 (de) Mittel und verfahren zur vorbeugung von durch chemotherapie ausgelöster alopezie
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
Xue et al. Exposure to acoustic stimuli promotes the development and differentiation of neural stem cells from the cochlear nuclei through the clusterin pathway
Chae et al. The study on the effect of nanoemulsion for the prevention and treatment of gingival inflammation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties